Thumbnail Image
Item

62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE

J-Y. Blay
; 
R.L. Jones
; 
H. Gelderblom
; 
S. George
; 
P. Schöffski
; 
M. von Mehren
; 
J.R. Zalcberg
; 
Y-K. Kang
; 
A.R. Abdul Razak
; 
J.C. Trent
... show 9 more
Citations
Altmetric:
Genre
Journal article
Date
2024-03-16
Advisor
Committee member
Group
Fox Chase Cancer Center (Temple University)
Department
Hematology and Medical Oncology
Subject
Permanent link to this record
https://scholarshare.temple.edu/handle/20.500.12613/11670
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
Mehren-JournalArticle-2024-03.pdf
Adobe PDF, 108.53 KB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1016/j.esmoop.2024.102452
Abstract
Background Ripretinib is a switch-control tyrosine kinase inhibitor approved in the US and EU for patients (pts) with gastrointestinal stromal tumor (GIST) who received prior treatment with 3 or more kinase inhibitors, including imatinib. Sunitinib is approved for advanced GIST after imatinib failure. In an exploratory analysis of baseline circulating tumor DNA (ctDNA) from the INTRIGUE trial, pts with primary mutations in KIT exon 11 and secondary mutations exclusively in KIT exons 17/18 (KIT exon 11 + 17/18) received clinical benefit from ripretinib but not sunitinib (Heinrich MC, et al. Nat Med. 2024). Here, we present final overall survival (OS) and updated safety in pts with KIT exon 11 + 17/18 mutations from INTRIGUE. Methods INTRIGUE (NCT03673501) is an open-label, phase 3 study of adults with advanced GIST who had disease progression on or intolerance to imatinib. Randomization was 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off). Final OS analysis was prespecified to occur with ≥200 and ≥145 events in the all-patient intention-to-treat (ITT) and KIT exon 11 ITT populations, respectively. Baseline peripheral whole blood was analyzed by Guardant360, a 74-gene ctDNA next-generation sequencing–based assay. Data cutoff was March 15, 2023. Results Of 453 pts, ctDNA was analyzed in an exploratory analysis for 362; 52 had mutations exclusively in KIT exon 11 + 17/18 (ripretinib, n = 27; sunitinib, n = 25). Pts with KIT exon 11 + 17/18 mutations had better OS with ripretinib vs sunitinib (median, not reached vs 17.5 months; HR, 0.37; 95% CI, 0.17 to 0.80; nominal P = 0.0091). Fewer of these pts had grade 3/4 drug-related treatment-emergent adverse events and serious adverse events with ripretinib vs sunitinib (33% vs 50% and 3.7% vs 13%, respectively). Median treatment duration in these pts for ripretinib vs sunitinib was 15.6 vs 3.0 months. Conclusions In this updated exploratory analysis from INTRIGUE, OS was longer for ripretinib vs sunitinib for pts with KIT exon 11 + 17/18 mutations identified by baseline ctDNA. The safety profile was consistent and more favorable for ripretinib vs sunitinib in these pts.
Description
Citation
J-Y. Blay, R.L. Jones, H. Gelderblom, S. George, P. Schöffski, M. von Mehren, J.R. Zalcberg, Y-K. Kang, A.R. Abdul Razak, J.C. Trent, S. Attia, A. Le Cesne, E. Davis, K. Sprott, P. Cox, M.L. Sherman, R. Ruiz-Soto, M. Heinrich, S. Bauer, 62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE, ESMO Open, Volume 9, Supplement 2, 2024, 102452, ISSN 2059-7029, https://doi.org/10.1016/j.esmoop.2024.102452. (https://www.sciencedirect.com/science/article/pii/S2059702924002205)
Citation to related work
Elsevier
Has part
ESMO Open, Vol. 9
ADA compliance
Embedded videos
License
Attribution-NonCommercial-NoDerivs CC BY-NC-ND
cbn